Table 5.

Treatment characteristics of treated patients following index nivolumab discontinuation according to their retreatment type.

	CT and/or TKI (n = 1,604)	Rechallenge (n = 110)	Resumption (n = 102)	Switch (n = 14)
					Median follow-up from index nivolumab initiation, months (range)	11.4 (1.0–73.4)	31.9 (7.6–70.4)	29.9 (5.1–73.9)	24.8 (4.4–63.4)
Duration of first LoT for LAM NSCLC, months, median (Q1–Q3)	3.3 (2.1–5.6)	3.3 (2.2–5.9)	3.6 (2.0–5.3)	4.6 (3.5–8.0)
ICI as 1L therapy for LAM NSCLC, n (%)	8 (0.5)	0 (0.0)	1 (1.0)	0 (0.0)
LoT of first nivolumab treatment received, n (%)
2L	948 (59.1)	72 (65.5)	58 (56.9)	7 (50.0)
3L	433 (27.0)	23 (20.9)	27 (26.5)	5 (35.7)
≥4L	223 (13.9)	15 (13.6)	17 (16.7)	2 (14.3)
Initial nivolumab treatment duration, months, median (Q1–Q3)	2.5 (1.4–5.1)	5.4 (2.7–10.6)	6.9 (3.0–18.2)	7.0 (6.0–16.1)
Reason for discontinuation, n (%)
Progression	1,350 (84.2)	86 (78.2)	25 (24.5)	11 (78.6)
Toxicity	101 (6.3)	8 (7.3)	23 (22.5)	–
Patient’s choice	3 (0.2)	–	7 (6.9)	–
Doctor’s choice/protocol-driven choice	156 (9.7)	10 (9.1)	43 (42.2)	2 (14.3)
Other	53 (3.3)	7 (6.4)	16 (15.7)	1 (7.1)
Median time from nivolumab discontinuation to retreatment with ICI, months (IQR)	NA	11.5 (7.0–19.5)	5.6 (3.1–10.3)	1.0 (0.9–1.1)
Median ICI retreatment duration, months (IQR)	NA	2.1 (1.1–5.2)	3.3 (1.4–6.5)	3.7 (1.7–5.6)

Follow-up was calculated as follows: (date of last medical information-index date)/30.4375. This is a time interval calculation; no censoring rule was applied.

1L, first line; 2L, second line; 2L+, second line or later; 3L, third line; ≥4L, fourth line or later; CT, chemotherapy; ICI, immune checkpoint inhibitor; IQR, interquartile range; LAM, locally advanced or metastatic; LoT, line of therapy; NA, not available; NSCLC, non-small cell lung cancer; Q, quartile; TKI, tyrosine kinase inhibitor.